Haijing Yang1,2,3, Zhiwei Huang2,3,4, Yuancheng Chen1,2,3, Yusong Zhu5, Guoying Cao1,2,3, Jingjing Wang1,2,3, Yan Guo2,3,4, Jicheng Yu1,2,3, Jufang Wu1,2,3, Lichuan Liu5, Jun Deng5, Jing Liu5, Harald Reinhart5, Jing Zhang2,3,4, Xiaojie Wu1,2,3. 1. Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China. 2. Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission, Shanghai, China. 3. National Clinical Research Center for Geriatric Diseases (Huashan Hospital), Shanghai, China. 4. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. 5. Zai Lab (Shanghai) Co., Ltd., Shanghai, China.
Abstract
Objective: Omadacycline is a new type of aminomethylcycline antibiotic, having a broad antibacterial spectrum. But the pharmacokinetic characteristics and safety profile of the Chinese population remain unknown. It is also unclear whether the US-approved treatment regimen is applicable for the Chinese population. Methods: In a randomized, double-blinded, placebo-controlled dose-escalated trial, the pharmacokinetics of omadacycline was evaluated by a non-compartmental and compartmental model. Monte Carlo simulations were performed using the pharmacokinetic data from the Chinese population to evaluate the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of the US FDA-approved dose regimen. Results: The three-compartment model successfully described the rapid distribution and slow elimination of omadacycline after the intravenous infusion (i.v.). The double-peak concentration-time curve of the oral absorption (p.o.) was explained by the two-compartment model with two absorption compartments. The steady-state AUC of 100 mg omadacycline i.v. and 300 mg omadacycline p. o. were 12.1 and 19.4 mg h/L, respectively. Pharmacokinetics/pharmacodynamics (PK/PD) analysis showed that the omadacycline dosing regimen with a loading dose (200 mg i.v. q24 h, 100 mg i.v. q12 h, 450 mg p. o. q24 h × 2 days or 300 mg p. o. q12 h) and maintenance dose (100 mg i.v. q24 h or 300 mg p. o. q24 h) could cover the main pathogens of the indications acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP): Staphylococcus aureus and Streptococcus pneumoniae. Also, omadacycline had showed a good safety profile in the Chinese population. Conclusions: With the evidence provided, omadacycline could be a novel treatment option to Chinese patients with ABSSSI and CABP.
Objective: Omadacycline is a new type of aminomethylcycline antibiotic, having a broad antibacterial spectrum. But the pharmacokinetic characteristics and safety profile of the Chinese population remain unknown. It is also unclear whether the US-approved treatment regimen is applicable for the Chinese population. Methods: In a randomized, double-blinded, placebo-controlled dose-escalated trial, the pharmacokinetics of omadacycline was evaluated by a non-compartmental and compartmental model. Monte Carlo simulations were performed using the pharmacokinetic data from the Chinese population to evaluate the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of the US FDA-approved dose regimen. Results: The three-compartment model successfully described the rapid distribution and slow elimination of omadacycline after the intravenous infusion (i.v.). The double-peak concentration-time curve of the oral absorption (p.o.) was explained by the two-compartment model with two absorption compartments. The steady-state AUC of 100 mg omadacycline i.v. and 300 mg omadacycline p. o. were 12.1 and 19.4 mg h/L, respectively. Pharmacokinetics/pharmacodynamics (PK/PD) analysis showed that the omadacycline dosing regimen with a loading dose (200 mg i.v. q24 h, 100 mg i.v. q12 h, 450 mg p. o. q24 h × 2 days or 300 mg p. o. q12 h) and maintenance dose (100 mg i.v. q24 h or 300 mg p. o. q24 h) could cover the main pathogens of the indications acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP): Staphylococcus aureus and Streptococcus pneumoniae. Also, omadacycline had showed a good safety profile in the Chinese population. Conclusions: With the evidence provided, omadacycline could be a novel treatment option to Chinese patients with ABSSSI and CABP.
Authors: Michael A Pfaller; Michael D Huband; Dee Shortridge; Robert K Flamm Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Cecilia G Carvalhaes; Michael D Huband; Harald H Reinhart; Robert K Flamm; Helio S Sader Journal: Antimicrob Agents Chemother Date: 2019-02-26 Impact factor: 5.191
Authors: William O'Riordan; Sinikka Green; J Scott Overcash; Ivan Puljiz; Symeon Metallidis; J Gardovskis; Lynne Garrity-Ryan; Anita F Das; Evan Tzanis; Paul B Eckburg; Amy Manley; Stephen A Villano; Judith N Steenbergen; Evan Loh Journal: N Engl J Med Date: 2019-02-07 Impact factor: 91.245
Authors: Haiying Sun; Lillian Ting; Surendra Machineni; Jens Praestgaard; Andreas Kuemmell; Daniel S Stein; Gangadhar Sunkara; Steven J Kovacs; Stephen Villano; S Ken Tanaka Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191
Authors: Steven J Kovacs; Lillian Ting; Jens Praestgaard; Gangadhar Sunkara; Haiying Sun; Daniel S Stein; S Ken Tanaka; Stephen Villano Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191